上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Rubitecan (Synonyms: RFS 2000; 9-Nitrocamptothecin) 纯度: 98.07%
Rubitecan (RFS 2000),喜树碱衍生物,是一种口服活性拓扑异构酶 I 抑制剂,具有广泛抗肿瘤活性,诱导蛋白质连接的 DNA 单链断裂,从而阻断分裂细胞中的 DNA 和 RNA 合成。
Rubitecan Chemical Structure
CAS No. : 91421-42-0
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥550 | In-stock | |
10 mg | ¥500 | In-stock | |
50 mg | ¥1200 | In-stock | |
100 mg | ¥2000 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Rubitecan 相关产品
•相关化合物库:
- Natural Product Library Plus
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Cell Cycle/DNA Damage Compound Library
- Natural Product Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Orally Active Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Alkaloids Library
- Anti-Lung Cancer Compound Library
- Rare Diseases Drug Library
生物活性 |
Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells[1][2][3]. |
IC50 & Target |
Topoisomerase I[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Rubitecan (RFS 2000) inhibits U-CH1, U-CH2, and CCL4 cells with IC50s 0.32, 0.83, and 7.7 µM, respectively[4]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
393.35 |
||||||||||||||||
Formula |
C20H15N3O6 |
||||||||||||||||
CAS 号 |
91421-42-0 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 125 mg/mL (317.78 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务